117 related articles for article (PubMed ID: 12495908)
41. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
42. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
44. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
Ozdemir E; Koc Y; Kansu E
Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
[No Abstract] [Full Text] [Related]
46. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
47. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
48. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Kim YJ; Kim DW; Lee S; Chung NG; Hwang JY; Kim YL; Min CK; Kim CC
Bone Marrow Transplant; 2004 Mar; 33(5):535-42. PubMed ID: 14716340
[TBL] [Abstract][Full Text] [Related]
49. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
50. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
51. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
52. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
[TBL] [Abstract][Full Text] [Related]
53. [Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia].
Miyazaki K; Kon S; Watanabe T; Togano T; Ohsaka M; Suzuki Y; Danbara M; Horie R; Kanda Y; Maruta A; Higashihara M
Rinsho Ketsueki; 2007 Apr; 48(4):297-304. PubMed ID: 17515120
[TBL] [Abstract][Full Text] [Related]
54. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
[No Abstract] [Full Text] [Related]
55. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
56. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann SR; Gately K; Conneally E; Lawler M
Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
[No Abstract] [Full Text] [Related]
57. [History, current status, and future prospects in clinical study of myeloid leukemia].
Ozawa K
Nihon Rinsho; 2009 Oct; 67(10):1841-6. PubMed ID: 19860177
[TBL] [Abstract][Full Text] [Related]
58. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
59. [Chronic myeloid leukemia--case report].
Hentrich M; Stoetzer OJ; Salat C; Ledderose G
Dtsch Med Wochenschr; 2002 Dec; 127(49):2617. PubMed ID: 12469273
[No Abstract] [Full Text] [Related]
60. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.
Nakasone H; Kanda Y; Takasaki H; Nakaseko C; Sakura T; Fujisawa S; Yokota A; Yano S; Usuki K; Maruta A; Abe D; Hoshino T; Takahashi S; Kanamori H; Okamoto S;
Leukemia; 2010 Jun; 24(6):1236-9. PubMed ID: 20428195
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
